Next generation antibody drugs: pursuit of the 'high-hanging fruit'

被引:612
作者
Carter, Paul J. [1 ]
Lazar, Greg A. [1 ]
机构
[1] Genentech Inc, Dept Antibody Engn, 1 DNA Way, San Francisco, CA 94080 USA
关键词
BLOOD-BRAIN-BARRIER; FC-GAMMA RECEPTOR; GROWTH-FACTOR RECEPTOR; HUMANIZED MONOCLONAL-ANTIBODY; SYNCYTIAL VIRUS-INFECTION; SERUM HALF-LIFE; BISPECIFIC-ANTIBODY; THERAPEUTIC ANTIBODIES; BINDING-AFFINITY; IN-VITRO;
D O I
10.1038/nrd.2017.227
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 090105 [作物生产系统与生态工程];
摘要
Antibodies are the most rapidly growing drug class and have a major impact on human health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of the best understood and most tractable cell surface and secreted targets with known roles in human diseases have been extensively exploited for antibody drug development. In this Review, we focus on emerging and novel mechanisms of action of antibodies and innovative targeting strategies that could extend their therapeutic applications, including antibody-drug conjugates, bispecific antibodies and antibody engineering to facilitate more effective delivery. These strategies could enable the pursuit of difficult to hit, less well-understood or previously undruggable targets - the 'high-hanging fruit'.
引用
收藏
页码:197 / 223
页数:27
相关论文
共 299 条
[1]
Leading Alzheimer's theory survives drug failure [J].
Abbott, Alison ;
Dolgin, Elie .
NATURE, 2016, 540 (7631) :15-16
[2]
How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches [J].
Agrahari, Vibhuti ;
Agrahari, Vivek ;
Mandal, Abhirup ;
Pal, Dhananjay ;
Mitra, Ashim K. .
EXPERT OPINION ON DRUG DELIVERY, 2017, 14 (10) :1145-1161
[3]
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs [J].
Andreev, Julian ;
Thambi, Nithya ;
Bay, Andres E. Perez ;
Delfino, Frank ;
Martin, Joel ;
Kelly, Marcus P. ;
Kirshner, Jessica R. ;
Rafique, Ashique ;
Kunz, Arthur ;
Nittoli, Thomas ;
MacDonald, Douglas ;
Daly, Christopher ;
Olson, William ;
Thurston, Gavin .
MOLECULAR CANCER THERAPEUTICS, 2017, 16 (04) :681-693
[4]
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations [J].
Arena, Sabrina ;
Siravegna, Giulia ;
Mussolin, Benedetta ;
Kearns, Jeffrey D. ;
Wolf, Beni B. ;
Misale, Sandra ;
Lazzari, Luca ;
Bertotti, Andrea ;
Trusolino, Livio ;
Adjei, Alex A. ;
Montagut, Clara ;
Di Nicolantonio, Federica ;
Nering, Rachel ;
Bardelli, Alberto .
SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (324)
[5]
Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing [J].
Arvedson, Tara L. ;
Balazs, Mercedesz ;
Bogner, Pamela ;
Black, Kurt ;
Graham, Kevin ;
Henn, Anja ;
Friedrich, Matthias ;
Hoffmann, Patrick ;
Kischel, Roman ;
Kufer, Peter ;
Lutterbuese, Ralf ;
Muenz, Markus ;
Raum, Tobias ;
Rattel, Benno ;
Rex, Karen ;
Rock, Dan ;
Thomas, Oliver ;
Wahl, Joachim ;
Wolf, Andreas ;
Coxon, Angela .
CANCER RESEARCH, 2017, 77
[6]
Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions [J].
Ashkenazi, Avi .
JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (02) :487-489
[7]
Rationale for anti-OX40 cancer immunotherapy [J].
Aspeslagh, Sandrine ;
Postel-Vinay, Sophie ;
Rusakiewicz, Sylvie ;
Soria, Jean-Charles ;
Zitvogel, Laurence ;
Marabelle, Aurelien .
EUROPEAN JOURNAL OF CANCER, 2016, 52 :50-66
[8]
Coming-of-Age of Antibodies in Cancer Therapeutics [J].
Ayyar, B. Vijayalakshmi ;
Arora, Sushrut ;
O'Kennedy, Richard .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2016, 37 (12) :1009-1028
[9]
4-1 BB agonists: multi-potent potentiators of tumor immunity [J].
Bartkowiak, Todd ;
Curran, Michael A. .
FRONTIERS IN ONCOLOGY, 2015, 5
[10]
Strategies and challenges for the next generation of antibody drug conjugates [J].
Beck, Alain ;
Goetsch, Liliane ;
Dumontet, Charles ;
Corvaia, Nathalie .
NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (05) :315-337